A correction may be in store for Standard BioTools Inc. (NASDAQ:LAB) shares?

In the latest session, Standard BioTools Inc. (NASDAQ: LAB) closed at $1.34 up 1.52% from its previous closing price of $1.32. In other words, the price has increased by $+0.0200 from its previous closing price. On the day, 142650 shares were traded. LAB stock price reached its highest trading level at $1.3522 during the session, while it also had its lowest trading level at $1.2500.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored

Ratios:

For a deeper understanding of Standard BioTools Inc.’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.50 and its Current Ratio is at 5.00.

Upgrades & Downgrades

Insider Transactions:

Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Aug 04 when Caligan Partners LP bought 255,173 shares for $1.75 per share. The transaction valued at 446,553 led to the insider holds 11,444,836 shares of the business.

Caligan Partners LP bought 46,009 shares of LAB for $80,056 on Aug 03. The 10% Owner now owns 11,189,663 shares after completing the transaction at $1.74 per share. On Aug 02, another insider, Caligan Partners LP, who serves as the 10% Owner of the company, bought 272,618 shares for $1.64 each. As a result, the insider paid 447,094 and bolstered with 11,143,654 shares of the company.

Valuation Measures:

For the stock, the TTM Price-to-Sale (P/S) ratio is 0.97.

Stock Price History:

Over the past 52 weeks, LAB has reached a high of $4.85, while it has fallen to a 52-week low of $0.92. The 50-Day Moving Average of the stock is 1.1946, while the 200-Day Moving Average is calculated to be 2.1284.

Shares Statistics:

For the past three months, LAB has traded an average of 314.29K shares per day and 330.85k over the past ten days. A total of 78.90M shares are outstanding, with a floating share count of 77.71M. Insiders hold about 1.10% of the company’s shares, while institutions hold 71.70% stake in the company. Shares short for LAB as of Oct 13, 2022 were 3.62M with a Short Ratio of 3.44M, compared to 3.82M on Sep 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 4.60% and a Short% of Float of 5.32%.

Earnings Estimates

There are 0 different market analysts currently analyzing its stock. On average, analysts expect EPS of $0 for the current quarter, with a high estimate of $0 and a low estimate of $0, while EPS last year was -$0.25. The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.

Analysts are recommending an EPS of between $0 and $0 for the fiscal current year, implying an average EPS of $0. EPS for the following year is $0, with 0 analysts recommending between $0 and $0.

Revenue Estimates

A total of 1 analysts believe the company’s revenue will be $26.5M this quarter.It ranges from a high estimate of $25.6M to a low estimate of $25.6M. As of the current estimate, Standard BioTools Inc.’s year-ago sales were $32.79M, an estimated decrease of -19.20% from the year-ago figure. For the next quarter, 1 analysts are estimating revenue of $18.78M, a decrease of -39.50% less than the figure of -$19.20% in the same quarter last year. There is a high estimate of $29.8M for the next quarter, whereas the lowest estimate is $29.8M.

A total of 1 analysts have provided revenue estimates for LAB’s current fiscal year. The highest revenue estimate was $124.4M, while the lowest revenue estimate was $124.4M, resulting in an average revenue estimate of $124.4M. In the same quarter a year ago, actual revenue was $130.58M, down -4.70% from the average estimate. Based on 1 analysts’ estimates, the company’s revenue will be $136.6M in the next fiscal year. The high estimate is $136.6M and the low estimate is $136.6M. The average revenue growth estimate for next year is up 9.80% from the average revenue estimate for this year.